Arrowhead Research ARWR Liability related to the sale of future royalties
Liability related to the sale of future royalties at other companies
Other financials
Where this comes from
Reported directly by Arrowhead Research in its filing.
Tagged under the XBRL concept arwr:RoyaltiesLiabilityNoncurrent.
The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arrowhead Research's liability related to the sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arrowhead Research's liability related to the sale of future royalties?
- Arrowhead Research (ARWR) reported liability related to the sale of future royalties of $383.83M in Q1 2026.
- How has Arrowhead Research's liability related to the sale of future royalties changed year-over-year?
- Arrowhead Research's liability related to the sale of future royalties increased by 9.0% year-over-year, from $352.28M to $383.83M.
- What does liability related to the sale of future royalties mean?
- Long-term obligations related to the sale or monetization of future royalty income.
- How do you interpret liability related to the sale of future royalties?
- An increase suggests the company has monetized future cash flows to raise immediate capital.
- How does liability related to the sale of future royalties compare across companies?
- Specific to biotech and pharma companies that use royalty financing to fund R&D.